# SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

> **NCT06442280** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Palermo** · enrollment: 544 (estimated)

## Conditions studied

- Heart Failure Acute
- Diabetes Type 2
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Dapagliflozin tablet
- **DRUG:** Hypertonic Saline Solution, 1 Ml
- **DRUG:** Furosemide Injection

## Key facts

- **NCT ID:** NCT06442280
- **Lead sponsor:** University of Palermo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-03-30
- **Target enrollment:** 544 (ESTIMATED)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06442280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06442280, "SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06442280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*